Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission - Methodologies in relation to their clinical situation

British Journal of Haematology

Volumn 158, Issue 5, 2012, Pages 569-580

  Hokland, Peter ^a   Ommen, Hans Beier ^a   Nyvold, Charlotte Guldborg ^a   Roug, Anne Stidsholt ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acute myeloid leukaemia; Minimal residual disease; Multicolour flow cytometry; Quantitative PCR; Sensitivity levels

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD SUBSTITUTION; BONE MARROW BIOPSY; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DISEASE ASSOCIATION; FLOW CYTOMETRY; GENE TARGETING; HUMAN; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; PATIENT ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; VALIDATION PROCESS;

COLOR; DECISION SUPPORT TECHNIQUES; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84865128557     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09203.x     Document Type: Review

References (62)

1. Abdelhamid, E., Preudhomme, C., Helevaut, N., Nibourel, O., Gardin, C., Rousselot, P., Castaigne, S., Gruson, B., Berthon, C., Soua, Z. & Renneville, A. (2012) Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leukemia Research, 36, 316-323.
2. Al-Mawali, A., Gillis, D., Hissaria, P. & Lewis, I. (2008) Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. American Journal of Clinical Pathology, 129, 934-945.
3. Al-Mawali, A., To, L.B., Gillis, D., Hissaria, P., Mundy, J. & Lewis, I. (2009) The presence of leukaemia-associated phenotypes is an independent predictor of induction failure in acute myeloid leukaemia. International Journal of laboratory hematology, 31, 61-68.
4. Babusikova, O., Glasova, M., Konikova, E. & Kusenda, J. (1996) Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia. Neoplasma, 43, 367-372.
5. Baer, M.R., Stewart, C.C., Dodge, R.K., Leget, G., Sulé, N., Mrózek, K., Schiffer, C.A., Powell, B.L., Kolitz, J.E., Moore, J.O., Stone, R.M., Davey, F.R., Carroll, A.J., Larson, R.A. & Bloomfield, C.D. (2001) High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood, 97, 3574-3580.
6. Bakker, A.B., van den Oudenrijn, S., Bakker, A.Q., Feller, N., van Meijer, M., Bia, J.A., Jongeneelen, M.A., Visser, T.J., Bijl, N., Geuijen, C.A., Marissen, W.E., Radosevic, K., Throsby, M., Schuurhuis, G.J., Ossenkoppele, G.J., de Kruif, J., Goudsmit, J. & Kruisbeek, A.M. (2004) C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Research, 64, 8443-8450.
7. Beillard, E., Pallisgaard, N., van der Velden, V.H., Bi, W., Dee, R., van der Schoot, E., Delabesse, E., Macintyre, E., Gottardi, E., Saglio, G., Watzinger, F., Lion, T., van Dongen, J.J., Hokland, P. & Gabert, J. (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia, 17, 2474-2486.
8. Bene, M.C., Nebe, T., Bettelheim, P., Buldini, B., Bumbea, H., Kern, W., Lacombe, F., Lemez, P., Marinov, I., Matutes, E., Maynadie, M., Oelschlagel, U., Orfao, A., Schabath, R., Solenthaler, M., Tschurtschenthaler, G., Vladareanu, A.M., Zini, G., Faure, G.C. & Porwit, A. (2011) Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia, 25, 567-574.
9. Beretta, C., Gaipa, G., Rossi, V., Bernasconi, S., Spinelli, O., Dell'Oro, M.G., Rizzari, C., Rambaldi, A., Biondi, A. & Cazzaniga, G. (2004) Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia. Leukemia, 18, 1441-1444.
10. Borowitz, M.J., Guenther, K.L., Shults, K.E. & Stelzer, G.T. (1993) Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. American Journal of Clinical Pathology, 100, 534-540.
11. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Büchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Löwenberg, B., Sanz, M.A., Head, D.R., Ohno, R., Bloomfield, C.D., LoCocco, F. & International Working Group for Diagnosis, S.o.R.C., Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 21, 4642-4649.
12. Cilloni, D., Gottardi, E., De Micheli, D., Serra, A., Volpe, G., Messa, F., Rege-Cambrin, G., Guerrasio, A., Divona, M., Lo Coco, F. & Saglio, G. (2002) Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia, 16, 2115-2121.
13. Cilloni, D., Renneville, A., Hermitte, F., Hills, R.K., Daly, S., Jovanovic, J.V., Gottardi, E., Fava, M., Schnittger, S., Weiss, T., Izzo, B., Nomdedeu, J., van der Heijden, A., van der Reijden, B.A., Jansen, J.H., van der Velden, V.H., Ommen, H., Preudhomme, C., Saglio, G. & Grimwade, D. (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. Journal of Clinical Oncology, 27, 5195-5201.
14. Derolf, A.R., Kristinsson, S.Y., Andersson, T.M., Landgren, O., Dickman, P.W. & Bjorkholm, M. (2009) Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood, 113, 3666-3672.
15. Dinardo, C.D. & Luger, S.M. (2012) Beyond morphology: minimal residual disease detection in acute myeloid leukemia. Current Opinion in Hematology, 19, 82-88.
16. Drach, J., Drach, D., Glassl, H., Gattringer, C. & Huber, H. (1992) Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry, 13, 893-901.
17. Freeman, S.D., Jovanovic, J.V. & Grimwade, D. (2008) Development of minimal residual disease-directed therapy in acute myeloid leukemia. Seminars in Oncology, 35, 388-400.
18. Gabert, J., Beillard, E., van der Velden, V.H., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J.M., Cave, H., Pane, F., Aerts, J.L., De Micheli, D., Thirion, X., Pradel, V., Gonzalez, M., Viehmann, S., Malec, M., Saglio, G. & van Dongen, J.J. (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia, 17, 2318-2357.
19. Gorello, P., Cazzaniga, G., Alberti, F., Dell'Oro, M.G., Gottardi, E., Specchia, G., Roti, G., Rosati, R., Martelli, M.F., Diverio, D., Lo Coco, F., Biondi, A., Saglio, G., Mecucci, C. & Falini, B. (2006) Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia, 20, 1103-1108.
20. Goulden, N., Virgo, P. & Grimwade, D. (2006) Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is now. British Journal of Haematology, 134, 273-282.
21. Griesinger, F., Piro-Noack, M., Kaib, N., Falk, M., Renziehausen, A., Troff, C., Grove, D., Schnittger, S., Buchner, T., Ritter, J., Hiddemann, W. & Wormann, B. (1999) Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome. British Journal of Haematology, 105, 241-255.
22. Grimwade, D., Jovanovic, J.V., Hills, R.K., Nugent, E.A., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., Rennie, K., Angell, R., Clark, R.E., Solomon, E., Lo-Coco, F., Wheatley, K. & Burnett, A.K. (2009) Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. Journal of Clinical Oncology, 27, 3650-3658.
23. Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J. & Burnett, A.K. (2010a) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 116, 354-365.
24. Grimwade, D., Vyas, P. & Freeman, S. (2010b) Assessment of minimal residual disease in acute myeloid leukemia. Current Opinion in Oncology, 22, 656-663.
25. Hochhaus, A., Lin, F., Reiter, A., Skladny, H., Mason, P.J., van Rhee, F., Shepherd, P.C., Allan, N.C., Hehlmann, R., Goldman, J.M. & Cross, N.C. (1996) Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood, 87, 1549-1555.
26. Hokland, P. & Ommen, H.B. (2011) Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood, 117, 2577-2584.
27. Inoue, K., Sugiyama, H., Ogawa, H., Nakagawa, M., Yamagami, T., Miwa, H., Kita, K., Hiraoka, A., Masaoka, T. & Nasu, K. (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood, 84, 3071-3079.
28. Inoue, K., Ogawa, H., Yamagami, T., Soma, T., Tani, Y., Tatekawa, T., Oji, Y., Tamaki, H., Kyo, T., Dohy, H., Hiraoka, A., Masaoka, T., Kishimoto, T. & Sugiyama, H. (1996) Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood, 88, 2267-2278.
29. Juliusson, G., Antunovic, P., Derolf, A., Lehmann, S., Mollgard, L., Stockelberg, D., Tidefelt, U., Wahlin, A. & Hoglund, M. (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood, 113, 4179-4187.
30. Kern, W., Danhauser-Riedl, S., Ratei, R., Schnittger, S., Schoch, C., Kolb, H.J., Ludwig, W.D., Hiddemann, W. & Haferlach, T. (2003) Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica, 88, 646-653.
31. Kern, W., Voskova, D., Schnittger, S., Schoch, C., Hiddemann, W. & Haferlach, T. (2004) Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia. The Hematology Journal, 5, 410-418.
32. Kern, W., Bacher, U., Haferlach, C., Schnittger, S. & Haferlach, T. (2010) The role of multiparameter flow cytometry for disease monitoring in AML. Best Practice & Research. Clinical haematology, 23, 379-390.
33. Krönke, J., Schlenk, R.F., Jensen, K.-O., Tschürtz, F., Corbacioglu, A., Gaidzik, V.I., Paschka, P., Onken, S., Eiwen, K., Habdank, M., Späth, D., Lübbert, M., Wattad, M., Kindler, T., Salih, H.R., Held, G., Nachbaur, D., von Lilienfeld-Toal, M., Germing, U., Haase, D., Mergenthaler, H.-G., Krauter, J., Ganser, A., Göhring, G., Schlegelberger, B., Döhner, H. & Döhner, K. (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. Journal of Clinical Oncology, 29, 2709-2716.
34. Laane, E., Derolf, A.R., Bjorklund, E., Mazur, J., Everaus, H., Soderhall, S., Bjorkholm, M. & Porwit-MacDonald, A. (2006) The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica, 91, 833-836.
35. Lacombe, F., Durrieu, F., Briais, A., Dumain, P., Belloc, F., Bascans, E., Reiffers, J., Boisseau, M.R. & Bernard, P. (1997) Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia, 11, 1878-1886.
36. Larsen, H.O., Roug, A.S., Just, T., Brown, G.D. & Hokland, P. (2012) Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up. Cytometry. Part B, Clinical Cytometry, 82, 3-8.
37. Lucio, P., Parreira, A., van den Beemd, M.W., van Lochem, E.G., van Wering, E.R., Baars, E., Porwit-MacDonald, A., Bjorklund, E., Gaipa, G., Biondi, A., Orfao, A., Janossy, G., van Dongen, J.J. & San Miguel, J.F. (1999) Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia, 13, 419-427.
38. Majeti, R. (2010) Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene, 30, 1009-1019.
39. Maurillo, L., Buccisano, F., Spagnoli, A., Del Poeta, G., Panetta, P., Neri, B., Del Principe, M.I., Mazzone, C., Consalvo, M.I., Tamburini, A., Ottaviani, L., Fraboni, D., Sarlo, C., De Fabritiis, P., Amadori, S. & Venditti, A. (2007) Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica, 92, 605-611.
40. Meyer, C., Kowarz, E., Hofmann, J., Renneville, A., Zuna, J., Trka, J., Ben Abdelali, R., Macintyre, E., De Braekeleer, E., De Braekeleer, M., Delabesse, E., de Oliveira, M.P., Cave, H., Clappier, E., van Dongen, J.J., Balgobind, B.V., van den Heuvel-Eibrink, M.M., Beverloo, H.B., Panzer-Grumayer, R., Teigler-Schlegel, A., Harbott, J., Kjeldsen, E., Schnittger, S., Koehl, U., Gruhn, B., Heidenreich, O., Chan, L.C., Yip, S.F., Krzywinski, M., Eckert, C., Moricke, A., Schrappe, M., Alonso, C.N., Schafer, B.W., Krauter, J., Lee, D.A., Zur Stadt, U., Te Kronnie, G., Sutton, R., Izraeli, S., Trakhtenbrot, L., Lo Nigro, L., Tsaur, G., Fechina, L., Szczepanski, T., Strehl, S., Ilencikova, D., Molkentin, M., Burmeister, T., Dingermann, T., Klingebiel, T. & Marschalek, R. (2009) New insights to the MLL recombinome of acute leukemias. Leukemia, 23, 1490-1499.
41. Miyachi, H., Tanaka, Y., Gondo, K., Kawada, T., Kato, S., Sasao, T., Hotta, T., Oshima, S. & Ando, Y. (1999) Altered expression of CD45 isoforms in differentiation of acute myeloid leukemia. American Journal of Hematology, 62, 159-164.
42. Oberdoerffer, S., Moita, L.F., Neems, D., Freitas, R.P., Hacohen, N. & Rao, A. (2008) Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein, hnRNPLL. Science, 321, 686-691.
43. Olesen, L.H., Clausen, N., Dimitrijevic, A., Kerndrup, G., Kjeldsen, E. & Hokland, P. (2004) Prospective application of a multiplex reverse transcription-polymerase chain reaction assay for the detection of balanced translocations in leukaemia: a single-laboratory study of 390 paediatric and adult patients. British Journal of Haematology, 127, 59-66.
44. Ommen, H.B., Nyvold, C.G., Braendstrup, K., Andersen, B.L., Ommen, I.B., Hasle, H., Hokland, P. & Ostergaard, M. (2008) Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. British Journal of Haematology, 141, 782-791.
45. Ommen, H.B., Schnittger, S., Jovanovic, J.V., Ommen, I.B., Hasle, H., Ostergaard, M., Grimwade, D. & Hokland, P. (2010) Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood, 115, 198-205.
46. Ossenkoppele, G.J., van de Loosdrecht, A.A. & Schuurhuis, G.J. (2011) Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. British Journal of Haematology, 153, 421-436.
47. Ostergaard, M., Olesen, L.H., Hasle, H., Kjeldsen, E. & Hokland, P. (2004a) WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. British Journal of Haematology, 125, 590-600.
48. Ostergaard, M., Stentoft, J. & Hokland, P. (2004b) A real-time quantitative RT-PCR assay for monitoring DEK-CAN fusion transcripts arising from translocation t(6;9) in acute myeloid leukemia. Leukemia Research, 28, 1213-1215.
49. Ostergaard, M., Nyvold, C.G., Jovanovic, J.V., Andersen, M.T., Kairisto, V., Morgan, Y.G., Tobal, K., Pallisgaard, N., Ozbek, U., Pfeifer, H., Schnittger, S., Grubach, L., Larsen, J.K., Grimwade, D. & Hokland, P. (2011) Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet. Leukemia, 25, 1168-1173.
50. van Rhenen, A., van Dongen, G.A., Kelder, A., Rombouts, E.J., Feller, N., Moshaver, B., Stigter-van Walsum, M., Zweegman, S., Ossenkoppele, G.J. & Jan Schuurhuis, G. (2007) The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood, 110, 2659-2666.
51. Rowley, J.D. (1982) Identification of the constant chromosome regions involved in human hematologic malignant disease. Science, 216, 749-751.
52. San Miguel, J.F., Vidriales, M.B., Lopez-Berges, C., Diaz-Mediavilla, J., Gutierrez, N., Canizo, C., Ramos, F., Calmuntia, M.J., Perez, J.J., Gonzalez, M. & Orfao, A. (2001) Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood, 98, 1746-1751.
53. Schnittger, S., Kern, W., Tschulik, C., Weiss, T., Dicker, F., Falini, B., Haferlach, C. & Haferlach, T. (2009) Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood, 114, 2220-2231.
54. Schnittger, S., Haferlach, C., Ulke, M., Alpermann, T., Kern, W. & Haferlach, T. (2010) IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood, 116, 5486-5496.
55. Stahl, T., Badbaran, A., Kröger, N., Klyuchnikov, E., Zabelina, T., Zeschke, S., Schafhausen, P., Schultz, W., Asenova, S., Smirnova, A., Wolschke, C., Ayuk, F., Zander, A.R., Fehse, B. & Bacher, U. (2010) Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis. Leukaemia & Lymphoma, 51, 1837-1843.
56. Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M.P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V.A., Sportoletti, P., Pettirossi, V., Mannucci, R., Elliott, O., Liso, A., Ambrosetti, A., Pulsoni, A., Forconi, F., Trentin, L., Semenzato, G., Inghirami, G., Capponi, M., Di Raimondo, F., Patti, C., Arcaini, L., Musto, P., Pileri, S., Haferlach, C., Schnittger, S., Pizzolo, G., Foa, R., Farinelli, L., Haferlach, T., Pasqualucci, L., Rabadan, R. & Falini, B. (2011) BRAF mutations in hairy-cell leukemia. New England Journal of Medicine, 364, 2305-2315.
57. Tobal, K., Frost, L. & Liu Yin, J.A. (2004) Quantification of DEK-CAN fusion transcript by real-time reverse transcription polymerase reaction in patients with t(6;9) acute myeloid leukemia. Haematologica, 89, 1267-1269.
58. Van Parijs, L., Refaeli, Y., Lord, J.D., Nelson, B.H., Abbas, A.K. & Baltimore, D. (2009) Retraction. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity, 30, 611.
59. van der Velden, V.H., Boeckx, N., Gonzalez, M., Malec, M., Barbany, G., Lion, T., Gottardi, E., Pallisgaard, N., Beillard, E., Hop, W.C., Hoogeveen, P.G., Gabert, J. & van Dongen, J.J. (2004) Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease-a study within the Europe Against Cancer Program. Leukemia, 18, 884-886.
60. Voskova, D., Schoch, C., Schnittger, S., Hiddemann, W., Haferlach, T. & Kern, W. (2004) Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry. Part B, Clinical Cytometry, 62, 25-38.
61. Voskova, D., Schnittger, S., Schoch, C., Haferlach, T. & Kern, W. (2007) Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia. Leukaemia & Lymphoma, 48, 80-88.
62. White, H.E., Matejtschuk, P., Rigsby, P., Gabert, J., Lin, F., Lynn Wang, Y., Branford, S., Muller, M.C., Beaufils, N., Beillard, E., Colomer, D., Dvorakova, D., Ehrencrona, H., Goh, H.G., El Housni, H., Jones, D., Kairisto, V., Kamel-Reid, S., Kim, D.W., Langabeer, S., Ma, E.S., Press, R.D., Romeo, G., Wang, L., Zoi, K., Hughes, T., Saglio, G., Hochhaus, A., Goldman, J.M., Metcalfe, P. & Cross, N.C. (2010) Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood, 116, e111-e117.